--- title: "Pulse Biosciences | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 434 K" type: "News" locale: "en" url: "https://longbridge.com/en/news/295139107.md" datetime: "2026-08-06T20:21:14.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/295139107.md) - [en](https://longbridge.com/en/news/295139107.md) - [zh-HK](https://longbridge.com/zh-HK/news/295139107.md) generator: "portal-rs" --- # Pulse Biosciences | 8-K: FY2026 Q2 Revenue Misses Estimate at USD 434 K Revenue: As of FY2026 Q2, the actual value is USD 434 K, missing the estimate of USD 533.33 K. EPS: As of FY2026 Q2, the actual value is USD -0.36, meeting the estimate of USD -0.36. EBIT: As of FY2026 Q2, the actual value is USD -25.87 M. Pulse Biosciences, Inc. announced certain financial and operational results for the fiscal quarter ended June 30, 2026, as detailed in a press release attached as Exhibit 99.1 to a Form 8-K filing on August 6, 2026. #### Revenue Total revenue for the three months ended June 30, 2026, was $0.4 million. Product revenue for the three months ended June 30, 2026, was $434 thousand, compared to $0 thousand for the same period in 2025. For the six months ended June 30, 2026, product revenue was $835 thousand, compared to $0 thousand for the same period in 2025. #### Operational Costs and Expenses Total GAAP costs and expenses for the three months ended June 30, 2026, were $25.7 million, an increase of $5.4 million from $20.3 million in the prior year period, primarily due to increased investment in clinical programs and compensation-related spending. Non-GAAP costs and expenses for the three months ended June 30, 2026, were $20.5 million, an increase of $5.7 million from $14.8 million in the prior year period, driven by increased clinical trial and compensation expenses. GAAP Research and development expenses for Q2 2026 were $16,976 thousand, up from $12,088 thousand in Q2 2025. GAAP Selling, general and administrative expenses for Q2 2026 were $8,457 thousand, compared to $8,187 thousand in Q2 2025. #### Net Loss GAAP net loss for the three months ended June 30, 2026, was - $24.7 million, compared to - $19.2 million for the three months ended June 30, 2025. Non-GAAP net loss for the three months ended June 30, 2026, was - $19.4 million, compared to - $13.7 million for the three months ended June 30, 2025. GAAP net loss for the six months ended June 30, 2026, was - $43,238 thousand, compared to - $35,963 thousand for the same period in 2025. Non-GAAP net loss for the six months ended June 30, 2026, was - $35,844 thousand, compared to - $25,127 thousand for the same period in 2025. #### Cash and Cash Equivalents Cash and cash equivalents totaled $101.6 million as of June 30, 2026. This compares to $106.3 million as of June 30, 2025, and $68.3 million as of March 31, 2026. The sequential increase of $33.3 million reflects net proceeds from the Company’s at-the-market (ATM) program during the quarter. #### Cash Flow from Operating Activities Cash used in operating activities in the second quarter of 2026 totaled - $18.7 million. This compares to - $12.8 million used in the same period in the prior year and - $14.6 million used in the first quarter of 2026. #### Capital Raising During Q2 2026, Pulse Biosciences, Inc. raised $46.8 million in net proceeds through an ATM program, with approximately $13 million from insiders and $33.8 million from outside investors. Subsequent to Q2, an additional $10.7 million in net proceeds was raised through the ATM, and $1.8 million in gross proceeds came from warrant exercises. The Company has established a new $75 million ATM facility and maintains an effective shelf registration statement for up to an additional $125 million, providing financing flexibility. #### Operational Highlights and Outlook Pulse Biosciences, Inc. anticipates completing enrollment for the NANOPULSE-AF U.S. IDE pivotal clinical study by early Q4, ahead of schedule, with a revised target of 164 evaluable patients. The company expects CE Mark submissions for the nPulse Cardiac Catheter System in the second half of 2026 and for the nPulse Cardiac Surgical System before the end of 2026, both with potential approval by mid-2027. Enrollment for the NANOCLAMP-AF study is projected to conclude by the end of the first half of 2027, while the PRECISE-Benign Thyroid Nodule study is expected to complete enrollment within the current month, and the PTMC feasibility study by year-end 2026. ### Related Stocks - [PLSE.US](https://longbridge.com/en/quote/PLSE.US.md) ## Related News & Research - [Pulse Biosciences Eyes AFib Breakthrough With Nanosecond PFA Platform](https://longbridge.com/en/news/296024769.md) - [This Onto Innovation Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday](https://longbridge.com/en/news/296102902.md) - [Pulse Biosciences Q2 net loss widens, cash position strengthens](https://longbridge.com/en/news/295139179.md) - [Pulse Biosciences advances NANOPULSE-AF pivotal study enrollment](https://longbridge.com/en/news/294218345.md) - [Pulse Biosciences to redeem remaining warrants after VWAP triggers; exercise window until July 13, 2026](https://longbridge.com/en/news/289332885.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**